Organon & Co. (OGN) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Organon reported revenue of $6.22B, down 2.9% from $6.40B the year before. Net income was $187.0M (a 3.0% net margin), or $0.72 per diluted share. Gross margin was 53.3% and operating margin was 25.6%. Operating activities generated $700.0M of cash, leaving $538.0M of free cash flow. At fiscal year end, Organon held $12.87B in total assets against $12.12B in total liabilities, including $574.0M of cash and equivalents.
Open the full interactive Organon financials → Quarterly statements, key ratios, valuation history and price charts.
Organon Key Stats
| Share Price | $13.77 |
|---|---|
| Market Cap | $3.72B |
| P/E Ratio | 19.1 |
| Dividend Yield | 0.48% |
| Revenue YoY Growth | -2.9% |
| 52-Week Range | $5.68 – $13.81 |
| Shares Outstanding | 262.6 million (basic, 2026 Q2) |
Organon Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $6.30B | $6.17B | $6.26B | $6.40B | $6.22B |
| Cost of Goods Sold | $2.38B | $2.29B | $2.52B | $2.69B | $2.90B |
| Gross Profit | $3.92B | $3.88B | $3.75B | $3.71B | $3.31B |
| Operating Income | $1.81B | $2.18B | $1.85B | $1.96B | $1.59B |
| Pre-Tax Income | $1.53B | $1.12B | $673.0M | $807.0M | $425.0M |
| Income Tax | $178.0M | $205.0M | -$350.0M | -$57.0M | $238.0M |
| Net Income | $1.35B | $917.0M | $1.02B | $864.0M | $187.0M |
| Diluted EPS | $5.31 | $3.59 | $3.99 | $3.33 | $0.72 |
Organon Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $1.60B | $1.51B | $1.46B | $1.56B |
| Net Income | $160.0M | -$205.0M | $146.0M | $108.0M |
| Diluted EPS | $0.61 | -$0.79 | $0.55 | $0.40 |
Organon Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $737.0M | $706.0M | $693.0M | $675.0M | $574.0M |
| Current Assets | $3.76B | $3.93B | $4.51B | $4.35B | $4.35B |
| Total Assets | $10.68B | $10.96B | $12.06B | $13.10B | $12.87B |
| Current Liabilities | $2.60B | $2.51B | $2.92B | $2.72B | $2.39B |
| Total Long-Term Debt | $9.13B | $8.91B | $8.76B | $8.88B | $8.64B |
| Total Liabilities | $12.19B | $11.85B | $12.13B | $12.63B | $12.12B |
| Shareholders' Equity | -$1.51B | -$892.0M | -$70.0M | $472.0M | $752.0M |
Organon Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | $2.16B | $858.0M | $799.0M | $939.0M | $700.0M |
| Cash From Investing | — | — | — | -$513.0M | -$390.0M |
| Cash From Financing | — | — | — | -$368.0M | -$561.0M |
| Free Cash Flow | $1.97B | $662.0M | $548.0M | $764.0M | $538.0M |
| Dividends Paid | $145.0M | $290.0M | $294.0M | $297.0M | $88.0M |
Figures from Organon's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Organon financials page for every line item.
Organon Company Profile
| Ticker | OGN |
|---|---|
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Headquarters | Jersey City, New Jersey |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001821825 |
Frequently Asked Questions
What was Organon's revenue in fiscal 2025?
Organon (OGN) reported revenue of $6.22B for fiscal 2025.
What is Organon's annual revenue history?
Organon's annual revenue by fiscal year: 2021: $6.30B; 2022: $6.17B; 2023: $6.26B; 2024: $6.40B; 2025: $6.22B.
What was Organon's net income in fiscal 2025?
Organon reported net income of $187.0M for fiscal 2025.
What was Organon's earnings per share (EPS) in fiscal 2025?
Organon's diluted EPS was $0.72 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Organon generate in fiscal 2025?
Organon generated $538.0M of free cash flow in fiscal 2025.
What was Organon's revenue last quarter?
In its most recent reported quarter (2026 Q2), Organon reported revenue of $1.56B.
How much debt does Organon have?
Organon reported $8.64B of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Organon are outstanding?
Organon reported a weighted average of 262.6 million basic shares outstanding in 2026 Q2.
What is Organon's market cap?
Based on its latest closing price, Organon (OGN) has a market capitalization of about $3.72B.
When does Organon's fiscal year end?
Organon's fiscal year end, as registered with the SEC, is December 31.
Where is Organon headquartered?
Organon lists its business address in Jersey City, New Jersey in its SEC filings.